$0.83
-0.02 (-1.77%)
Open$0.84
Previous Close$0.85
Day High$0.91
Day Low$0.81
52W High$4.47
52W Low$0.65
Volume—
Avg Volume19.6K
Market Cap6.71M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,391.0% upside
Current
$0.83
$0.83
Target
$12.39
$12.39
$9.33
$12.39 avg
$15.15
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.16M | 3.05M | 3.43M |
| Net Income | -41,291 | -50,098 | -44,694 |
| Profit Margin | -1.3% | -1.6% | -1.3% |
| EBITDA | -71,807 | -61,818 | -76,890 |
| Free Cash Flow | -34,920 | -36,621 | -42,296 |
| Rev Growth | +21.0% | -5.0% | +24.8% |
| Debt/Equity | 0.35 | 0.39 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |